Novo Nordisk has told the world it expects patients to lose “at least 25%” of their body weight on its experimental drug CagriSema. On Friday, Novo released the results of a large Phase 3 trial of the ...

Wall Street was poised to open with significant losses on Friday as the possibility of government shutdown right before ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...

Eli Lilly’s Kisunla Approved in China, Paving the Way for Innovative Alzheimer’s Treatment Options Elon Musk Lights Up Tesla Buzz with $690.42 Price Target and $2 Trillion Market Cap Forecast ...

As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...

The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes ...

When individual investors are asked about investment vehicles for “innovation,” the Invesco QQQ ETF and the ARKK Innovation ...

China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option ...

News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen ...

The Hansoh deal will let Merck compete in the crowded oral GLP-1 space alongside fellow pharma giants Eli Lilly, Novo Nordisk ...

The company states: “Eli Lilly (LLY) announced that the National Medical Products Administration in China has approved Kisunla, an Alzheimer’s treatment for adults with early symptomatic Alzheimer’s ...